Acquisition and loss of molecular response; patients diagnosed September 2004–August 2011 and followed until 1st April 2013
| Achieved response/TKI treated (%) | Loss of response/achieved response (%) | Deaths/achieved response (%) | Loss of response plus deaths*/achieved response (%) | HR† (95% CI) for loss of response plus deaths | ||
|---|---|---|---|---|---|---|
| Unadjusted | Adjusted† | |||||
| Major molecular response (MMR=≤0.1%) | ||||||
| Deprivation quintile | ||||||
| 1–3 | 100/140 (71.4) | 28/100 (28.0) | 8/100 (8.0) | 35/100 (35.0) | 1.0 | 1.0 |
| 4–5 (less affluent) | 56/94 (59.6) | 20/56 (35.7) | 8/56 (14.3) | 27/56 (48.2) | 1.68 (1.03 to 2.78) | 1.71 (1.03 to 2.84) |
| (MR=≤1.0%) | ||||||
| Deprivation quintile | ||||||
| 1–3 | 115/140 (82.1) | 15/115 (13.0) | 8‡/115 (7.0) | 22/115 (19.1) | 1.0 | 1.0 |
| 4–5 (less affluent) | 67/94 (71.3) | 13/67 (19.4) | 9‡/67 (13.4) | 21/67 (31.3) | 1.78 (0.98 to 3.24) | 1.90 (1.03 to 3.49) |
*3 Deaths occurred in patients with a recorded loss of response.
†Adjusted for age and sex.
‡4/8 Deaths in deprivation categories 1–3 and 9/9 deaths in deprivation categories 4–5 were CML related (death certificates).
CML, chronic myeloid leukaemia; MMR, major molecular response; MR, molecular response; TKI, tyrosine kinase inhibitors.